ImmunityBio (IBRX) Non-Current Assets (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Non-Current Assets data on file, last reported at $193.7 million in Q1 2026.

• On a quarterly basis, Non-Current Assets changed 0.47% year-over-year to $193.7 million in Q1 2026; TTM through Mar 2026 was $764.1 million, a 3.99% decrease from a year earlier, with the FY2025 full-year figure at $187.0 million, down 5.71% from the prior year.
• Non-Current Assets for Q1 2026 stood at $193.7 million, up from $187.0 million in the prior quarter.
• Over the last five years, Non-Current Assets for IBRX reached as high as $229.9 million in Q1 2023 and fell as low as $177.2 million in Q1 2022.
• Historically, Non-Current Assets has averaged $203.4 million across 5 years, with a median of $201.5 million in 2024.
• Across the five-year window, Non-Current Assets surged 74.92% in 2022 and retreated 10.85% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $221.8 million in 2022, then declined by 5.15% to $210.4 million in 2023, then retreated by 5.71% to $198.3 million in 2024, then retreated by 5.71% to $187.0 million in 2025, then increased by 3.56% to $193.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $193.7 million in Q1 2026, $187.0 million in Q4 2025, and $189.5 million in Q3 2025.